Please provide your email address to receive an email when new articles are posted on . Within the studied cohort, males had a higher IPF death rate than females. Researchers observed eight industries ...

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Roughly one in five (21 percent) of idiopathic pulmonary fibrosis (IPF) deaths might be related to occupational exposures, according to research published in the March 6 issue of the U.S. Centers for ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Two differing nerandomilast doses were assessed against ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

Panelists discuss how antifibrotic therapies for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) slow disease progression despite challenges with cost, tolerability, and ...

Could targeting a enzyme play a role in slowing lung fibrosis? Boehringer Ingelheim’s research into PDE4B is offering ...